Salbutamol pretreatment does not change eosinophil percentage and eosinophilic cationic protein concentration in hypertonic saline‐induced sputum in asthmatic subjects
- 1 May 1999
- journal article
- clinical trial
- Published by Wiley in Clinical and Experimental Allergy
- Vol. 29 (5) , 712-718
- https://doi.org/10.1046/j.1365-2222.1999.00519.x
Abstract
Background Sputum induction by inhalation of hypertonic saline (HS) is usually preceded by β2‐agonist pretreatment, to prevent severe bronchoconstriction. Objective To evaluate whether salbutamol pretreatment may influence cell counts and concentrations of soluble mediators in induced sputum. Methods We studied 22 patients who randomly underwent HS sputum induction after pretreatment with either 200 μg salbutamol or placebo. Sputum was induced by means of HS inhalation (3, 4, 5% NaCl, 10 min each), measuring FEV1 every 5 min until it fell ≥ 20% from baseline. Collected sputum was diluted 1 : 1 with 0.1% DTT, incubated at 37 °C for 20 min, and total and differential cell counts were measured. ECP and histamine levels were measured in the supernatant. Results Sputum volume, percentages of inflammatory cells, squamous cell counts and quality of the slides were not different after the two pretreatments, while sputum total inflammatory cells after salbutamol tended to be higher than after placebo (8.3 [1–41] ×106 vs 6.3[0.2–40] ×106; P = 0.09). Eosinophilic cationic protein (ECP) did not significantly change (260 [8–900] μg/L after salbutamol vs 200 [8–800] μg/L, n = 19), while histamine levels tended to be lower after salbutamol (140.9 [39.9–236.5] n m) than after placebo (190.4 [72.2–322.6] n m, P = 0.09, n = 17). The airway response to HS inhalation was significantly greater after placebo and the duration of the test was significantly different (median: 15 min after placebo and 30 min after salbutamol). Similar results were obtained when patients who differed for more than 15 min in the duration of HS‐inhalation in the two tests were selected (n = 11). Conclusion Salbutamol pretreatment reduces the severity of bronchoconstriction induced by HS inhalation without significantly affecting the percentages of inflammatory cells and the levels of soluble mediators in induced sputum.Keywords
This publication has 20 references indexed in Scilit:
- Salmeterol inhibition of mediator release from human lung mast cells by β-adrenoceptor-dependent and independent mechanismsBritish Journal of Pharmacology, 1998
- Comparison between hypertonic and isotonic saline‐induced sputum in the evaluation of airway inflammation in subjects with moderate asthmaClinical and Experimental Allergy, 1996
- The evaluation of a cell dispersion method of sputum examinationClinical and Experimental Allergy, 1994
- Analysis of cellular and biochemical constituents of induced sputum after allergen challenge: A method for studying allergic airway inflammationJournal of Allergy and Clinical Immunology, 1994
- The effect of salmeterol on the early‐ and late‐phase reaction to bronchial allergen and postchallenge variation in bronchial reactivity, blood eosinophils, serum eosinophil cationic protein, and serum eosinophil protein XAllergy, 1993
- Inhibition by salmeterol of increased vascular permeability and granulocyte accumulation in guinea-pig lung and skinBritish Journal of Pharmacology, 1992
- Use of induced sputum cell counts to investigate airway inflammation in asthma.Thorax, 1992
- Hypertonic saline increases vascular permeability in the rat trachea by producing neurogenic inflammation.Journal of Clinical Investigation, 1990
- Inhalation provocation tests using nonisotonic aerosolsJournal of Allergy and Clinical Immunology, 1989
- Inhibition of IgE‐dependent histamine release from human dispersed lung mast cells by anti‐allergic drugs and salbutamolBritish Journal of Pharmacology, 1987